ICO Hospitalet

Barcelona 8908

2 studies enrolling now · 6 studies all time

What they study most

Acinar Cell Carcinoma, Advanced Cancer, Advanced Solid Tumor, Colorectal Cancer (CRC), Endometrial Cancer, Fallopian Tube Cancer, GIST, HER2-Positive Primary Breast Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer

Studies at this site

• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies — Recruiting now
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors — Running, not enrolling
• Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC. — Stopped early
• Derazantinib and Atezolizumab in Patients With Urothelial Cancer — Completed